Haleon PLC (HLN)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 381.20 |
|---|---|
| 52-week range | 317.80 – 433.60 |
| Return, 1 month / 3 months | +11.6% / +6.1% |
| Return, 1 year / 3 years | +10.7% / +20.0% |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 22.7% |
| Worst drawdown (1 year) | -20.9% |
| Average daily value traded | 9,416.06M GBX |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Haleon is a consumer healthcare company based in the United Kingdom that makes and markets branded over-the-counter products. Its range includes oral care items such as toothpaste and mouthwash, pain relief medicines, cold and flu remedies, digestive treatments, vitamins and supplements, and skin health products. It serves everyday consumers through pharmacies, supermarkets, and other retail outlets in many countries, and it also supplies healthcare professionals with some of its brands.
The shares are listed on the London Exchange in UK under the code HLN, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Haleon PLC (HLN) trades on the London Exchange in UK. It last closed at GBX 381.20 on 23 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 775 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.7% and over the last three months it rose 6.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 63 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.7% | ||
| From 52-week high | -7.2% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.1% | ||
| 6-month return | 9.1% | ||
| 12-month return, skipping the last month | -0.8% | ||
| Stability (higher is calmer) | 76 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.9% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 9,416.06M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 22 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 4 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.6% |
|---|---|
| 1 month | +11.6% |
| 3 months | +6.1% |
| 6 months | +9.1% |
| 1 year | +10.7% |
| 3 years | +20.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 352.50 / 357.10 |
|---|---|
| Golden / death cross (60 days) | Death, 23 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.76 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Aug 2026 | GBP 0.0240 |
| 9 Apr 2026 | GBP 0.0490 |
| 14 Aug 2025 | GBP 0.0220 |
| 24 Apr 2025 | GBP 0.0460 |
| 15 Aug 2024 | GBP 0.0200 |
| 14 Mar 2024 | GBP 0.0420 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.